Androgen replacement therapy

Drug Profile

Androgen replacement therapy

Alternative Names: Andrin; Dihydrotestosterone transdermal gel - ASCEND

Latest Information Update: 04 Aug 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Besins International
  • Developer ASCEND Therapeutics
  • Class Androstanols; Testosterone congeners
  • Mechanism of Action Testosterone congener stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Benign prostatic hyperplasia; Hypogonadism

Most Recent Events

  • 14 Nov 2006 DHT gel is still in phase II trials for Hypogonadism in USA
  • 29 Oct 2004 Phase-II clinical trials in Hypogonadism in USA (Transdermal)
  • 16 Jul 2004 Phase-II clinical trials in Benign prostatic hyperplasia in Australia (Transdermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top